The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)
This funding opportunity announcement (FOA) focuses on the role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection. The goal is to increase our knowledge through mechanistic, epidemiological, or translational studies that examine how EBV promotes NHL or HD initiation, progression, and the resulting disease sequelae and to provide insights into mechanistic differences in the relationship between EBV infection and lymphomagenesis in HIV+ versus HIV- persons. Research project U01s funded through this PAR will form a cooperative group, the Epstein Barr Virus associated Lymphoma Consortium (EALC).
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: Dec. 15, 2021; Dec. 15, 2022; Dec. 15, 2023
PAR-21-348 Expiration Date December 16, 2023